Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00594126 · ClinicalTrials.gov registry record · Phase 1

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Geron Corporation.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
3
Study locations

NCT00594126 is a Phase 1 study of Multiple Myeloma that has completed, run by Geron Corporation. The registered enrollment target is 20 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00594126, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Geron Corporation.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered to patients with refractory or relapsed multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Imetelstat Sodium (GRN163L)

Study Locations (3)

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University - Baltimore

Massachusetts

  • Dana Farber Cancer Institute - Boston

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2007-11
Est. Completion 2011-07
Phase Phase 1

Sponsor

Geron Corporation

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00594126

The ClinicalTrials.gov registry entry for NCT00594126 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Imetelstat Sodium (GRN163L) is the first listed.

NCT00594126 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT00594126 about?

NCT00594126 is a clinical study titled "Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma". The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered to patients with refractory or relapsed multiple myeloma.

What is the current status of trial NCT00594126?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-11. Estimated completion is 2011-07.

What conditions does trial NCT00594126 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00594126?

The interventions under investigation include: Imetelstat Sodium (GRN163L) (DRUG).

Who is sponsoring clinical trial NCT00594126?

This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00594126 being conducted?

This trial has 3 study locations across Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.